Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.60
Bid: 21.20
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 0.80 (3.77%)
Open: 21.60
High: 21.60
Low: 21.60
Yest. Close: 21.60
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

Thu, 3rd Sep 2020 15:31

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.
The AIM-traded firm said it had entered into an exclusive licence agreement with Saiba and DeepVax to use their patented VLP technology platform, to develop and commercialise vaccines targeting solid cancer tumours, atopic dermatitis, asthma, and psoriasis.

Allergy said it had an existing license agreement with Saiba and DeepVax, exclusively licensing their technology for the development of a new VLP vaccine immunotherapy treatment for peanut allergy sufferers.

Submission of the clinical trial application for that candidate vaccine was expected in 2021, following previously-published, "encouraging" preclinical results.

The company said the new licensing agreement with Saiba and DeepVax includes upfront payments, which would not be material in group terms, as well as further milestone payments at key points in clinical development, and royalty payments if candidates are commercialised.

Allergy's board said it believed the use of VLP technology was a novel approach to generating active vaccines against appropriate cytokines - the small proteins that are crucial to cell signalling in the immune pathway for many diseases.

Current approaches, including monoclonal antibodies, could have the limitation of a transient effect, meaning repeated treatments would be required.

The group said it believed the VLP approach could offer a number of benefits, including sustained efficacy and a much lower cost per patient.

In pursuing the approach, Allergy Therapeutics said it was intending to investigate the potential of combining VLP technology with its adjuvant systems including microcrystalline tyrosine (MCT).

Adjuvant technologies were described by the company as a "key element" of its strategy, having the potential to create immunotherapies that acted faster, generated a sustained response, and worked more efficiently than traditional therapies.

Prior studies had already demonstrated the group's adjuvant technologies had a "synergistic effect" in certain disease models.

The group said it planned to evaluate the new therapies via initial pre-clinical evaluation and, should those studies be successful, would explore future clinical development and potential partnering opportunities, alongside discussions with regulatory authorities.

"This is a very exciting opportunity for Allergy Therapeutics, enabling us to take the first steps into the broader vaccine field using a technology platform that we are familiar with and already using in our peanut allergy candidate vaccine," said chief executive officer Manuel Llobet.

"While the allergy field remains our core focus, we believe VLP technology has potential across multiple therapies areas where there remains huge unmet need among patients.

"This is an opportunity to provide significant improvements to current treatment approaches used for a number of solid cancer and immune conditions and a more convenient treatment option for patients, which is the founding principle of our business."

At 1524 BST, shares in Allergy Therapeutics were up 6.78% at 19.22p.

More News

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

6 May 21 19:25

Allergy Therapeutics completes treatment in G309 field study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.

6 May 21 15:34

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

3 Mar 21 19:14

Allergy Therapeutics reports record pre-R&D operating profit

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.

3 Mar 21 13:23

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

13 Jan 21 13:29

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

5 Jan 21 18:01

Allergy Therapeutics begins peanut allergy vaccine study

(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.

5 Jan 21 16:44

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

8 Dec 20 21:07

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

1 Dec 20 16:06

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

20 Nov 20 14:51

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

26 Oct 20 14:17

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

26 Oct 20 13:37

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

23 Sep 20 14:02

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

4 Sep 20 19:39

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

3 Sep 20 15:31

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.